What presentation is useful for safety and efficacy data across multiple trials by indications or subgroups?

• A. Tabular summaries of adverse drug reactions for all clinical trials by indications and subgroups
• B. Narrative only with text
• C. No ADR data
• D. Only positive ADRs

Answer: (A)

Presenting safety and efficacy data across multiple trials by indication or subgroup is most effectively done with tabular summaries that compile adverse drug reactions for all trials, organized by indication and subgroup. The table format provides a concise, standardized way to compare how safety signals and efficacy outcomes vary across different populations and study designs, making it easier to spot patterns, compare incidence rates, and support regulatory submissions or decision-making. A narrative-only report lacks the structured, side-by-side view that tables offer; omitting ADR data hides important safety information; and reporting only positive ADRs would bias the understanding of the full safety profile.